NephroGenex Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Crossject SA raises 17 million euros in IPO
Crossject SA:Raises 17 million euros in IPO on Alternext Paris.The total demand was for 56.3 million euros, the offer was 4.4 times oversubscribed.The price of the offer was 8.38 euros per share.
Latest Developments for NephroGenex Inc
Latest Key Developments in Biotechnology
- Neovacs SA announces positive iDSMB review of phase IIb study of TNF-Kinoid in Rheumatoid Arthritis
- PDL BioPharma Inc gives Q1 2014 revenue guidance in line with analysts' estimates
- Codexis Inc gives FY 2014 revenue guidance
- OXiGENE Inc announces positive topline results from randomized phase 2 study GOG186I of Zybrestat in combination with Avastin for recurrent ovarian cancer
- Share this
- Digg this